-
WHO approves Novavax vaccine to re-enter emergency use list
Time of Update: 2022-01-11
(NASDAQ: NVAX), a company dedicated to the next generation of severe infectious diseases The vaccine development and commercialization biotechnology company announced today that its recombinant protein nanoparticle vaccine NVX-CoV2373 containing Matrix-M adjuvant has been approved by the World Health Organization to be included in the Emergency Use List (EUL) .
-
Nafuraphine Hydrochloride Orally Disintegrating Tablet, a joint product of 3SBio and Toray of Japan, submitted a marketing application
Time of Update: 2022-01-11
today announced the company’s submission of navura hydrochloride to the China National Medical Products Administration (NMPA) The new drug marketing application of Ephene orally disintegrating tablets (R&D code: TRK-820, Japanese brand name "REMITCH ® ") has been accepted, and it is used to improve the pruritus of hemodialysis patients whose curative effect is not satisfactory .
-
The BIPS2021 Global Biomedical Innovation Pioneer China Summit was successfully held in Shanghai
Time of Update: 2022-01-11
Hui Aimin, Executive President and Global R&D Director of Fosun Pharma, gave a speech on the international development strategy of China's innovative drugs, and shared Fosun Pharma’s clinical needs-oriented R&D strategy and the practice of R&D innovation and internationalization.
-
Cell Industry Conference 2022 conference plan is released: April Shanghai, August Shenzhen, November Wuhan, looking forward to your joining!
Time of Update: 2022-01-11
In recent years, modern life sciences and biotechnology have made a series of important advances and major breakthroughs, especially the rapid development of cell therapy technology with stem cells an
-
Eddie Pharmaceuticals and PerkinElmer reached a strategic cooperation
Time of Update: 2022-01-11
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
At the same time, the two parties will carry out clinical research and market development cooperation on the diagnosis and treatment of AIDS .
-
Newly announced clinical trial results show that spesolimab significantly improves the signs and symptoms of acute onset of generalized pustular psoriasis, a rare and life-threatening skin disease
Time of Update: 2022-01-10
prntblns{ BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt } The latest clinical trial data published today in the "New England Journal of Medicine" shows that the new IL-36 antibody therapy spesolimab can effectively and quickly treat acute attacks in adults with generalized pustular psoriasis (GPP) .
-
Everyone Insurance: China’s basic pension has experienced 17 consecutive increases, but pensions need to pay attention to these
Time of Update: 2022-01-10
Close to medical care, close to children, old-age care and more love for the city centerWhen it comes to the retirement community, many elderly people show concern .
-
Shanghai Hutchison Pharmaceuticals was selected as "Top 100 Chinese Patent Medicine Companies" and Shexiang Baoxin Pills were listed on "2021 Clinical Value Chinese Patent Medicine Brand List"
Time of Update: 2022-01-10
Shanghai Hutchison Pharmaceuticals adheres to the mission of "innovating traditional Chinese medicines and serving healthy China", and continuously promotes the modernization and internationalization of Chinese medicines .
-
Luye Pharma's new antidepressant drug Ansufaxine Hydrochloride Sustained-Release Tablets Phase II Clinical Data Released
Time of Update: 2022-01-10
The main results are as follows:· LY03005 reaches the main efficacy endpoint, and has a good effective rate and remission rateThe primary efficacy endpoint showed that the total scores of the 17 Hamilton Depression Rating Scale (HAM-D17) in each dose group of LY03005 at the end of the 6th week were better than those of the placebo group, and the difference was statistically significant (P<0.
-
Corning Jerry KN046 completed a phase II registration clinical trial for the first patient in the United States
Time of Update: 2022-01-10
The company's product pipeline includes 15 highly differentiated anti-tumor drug candidates with independent intellectual property rights, mainly double antibodies, and a Covid-19 multifunctional antibody, four of which are in China, the United States, Japan, and Australia It is in clinical phase I-III .
-
Tengshengbo drug BRII-179 was used for the functional cure of hepatitis B in phase 2a/2b clinical completion of the first subject administration
Time of Update: 2022-01-10
HK), a multinational company dedicated to the development of innovative therapies for patients’ unmet needs and major public health diseases, today announced that BRII-179 (VBI-2601) treats chronic hepatitis B virus (HBV) infection Phase 2a/2b clinical trials have completed the first subject's administration .
-
Yuyue Medical won the "2021 First Financial Innovation Competitive Enterprise" Innovation-driven high-quality development
Time of Update: 2022-01-10
Yuyue Medical won the "2021 CBN Innovation Competitive Enterprise" award In the past eight years, CBN has visited hundreds of listed companies in depth, creating and perfecting an evaluation model for continuous innovation .
-
Lion Biotech obtained FDA Fast Track Certification: Application of HBV-specific TCR-T in the treatment of hepatocellular carcinoma
Time of Update: 2022-01-10
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
S. FDA for Fast Track, as the world's first company to use mRNA electrotransmission technology to target the surface of hepatitis B Antigen TCR-T cell therapy is used to treat hepatitis B-related hepatocellular carcinoma (HCC) .
-
CStone Pharmaceuticals announces that AYVAKIT (avapritinib), a precision targeted drug for gastrointestinal stromal tumors, has been approved in Hong Kong, China
Time of Update: 2022-01-09
<> /* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prne
-
WuXi Biologics and ImmuneOncia of South Korea signed a memorandum of understanding for the development and production of anti-PD-L1/CD47 bispecific antibodies
Time of Update: 2022-01-09
62em; font-family:"Arial"; color:black; margin:0in; } </>Shanghai, China and Seoul, South Korea, December 28, 2021/PRNewswire/ - The world's leading open biopharmaceutical technology platform company WuXi Biologics (WuXi Biologics, 2269.
-
The investigative Alzheimer's disease treatment LECANEMAB was designated by the U.S. FDA for fast-track application
Time of Update: 2022-01-09
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.
The title of breakthrough therapy and the fast-track application designation are two FDA plans to promote and accelerate the development of new drugs to meet those unmet medical needs (for example: Alzheimer's disease) for the treatment of serious or life-threatening diseases Disease and provide opportunities for frequent interaction with the FDA .
-
Codex DNA fully automated synthesis of SARS-CoV-2 full-length genome
Time of Update: 2022-01-09
Codex DNA released the SARS-CoV-2 full-length synthetic genome of the highly mutated and infectious Omicron variant (B.
Through the Omicron variant, Codex DNA provides a complete catalog of 14 SARS-CoV-2 synthetic genomes, as well as a customized SARS-CoV-2 genome to support researchers .
-
Takara shares mRNA vaccine research solutions
Time of Update: 2022-01-08
Item No. product nameSpecification2540AT7 RNA Polymerase5,000 U2520ASP6 RNA Polymerase3,000 U2181Poly(A) Polymerase20 U2270ARecombinant DNase I (RNase-free)1,000 U2313ARecombinant RNase Inhibitor5,000 U※Check the complete content of the solution through the "Takara Bio China official website" to learn about restriction enzymes, ribonucleotides and other product informationmRNA transfectionBefore conducting animal experiments, transfecting mRNA into cells is one of the methods to initially verify whether the synthesized mRNA is effective .
-
Data and calculations make Guangxi medical insurance more accurate, precise and convenient
Time of Update: 2022-01-08
<> /* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prne
-
"2021 China High Net Worth People's Health Investment White Paper" released
Time of Update: 2022-01-08
China Merchants Cigna Life's break-through strategy is to find out the positioning of insurance services in health management and wealth inheritance, starting from the needs and pain points of different high-net-worth individuals, and truly let the protection play a role .
